The specter of generic competition has consistently loomed around copyright’s iconic drug, PDE5 Inhibitor, sparking questions about the outlook of similar drug investments. While first periods saw impressive gains, the intellectual property expiration has opened the way for cheaper substitutes, likely lowering profitability and posing a signific… Read More